207 results about "Cannabidiol" patented technology

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

An injectable cannabidiol formulation for non-IV parenteral administration comprising, consisting essentially of, or consisting of: (a) a solvent system consisting of (i) an effective amount of at least one triglyceride oil; and (ii) an effective amount of at least one C1-C3 alkyl ester of a C6-C22 fatty acid; and (b) an effective amount of cannabidiol; wherein the formulation is free of water and ethanol, has a viscosity less than about 35 cP, and is phase stable and chemically stable. The formulation can further comprise at least one additional pharmaceutically acceptable excipient. Kits containing the formulation are also described.

The invention discloses a preparation method of a cannabidiol compound, the method synthesizes the cannabidiol compound from a resorcinol derivative and menthyl-2, 8-diene-1-ol under the catalysis of a condensing agent, and the method has the advantages of simple operation, high alkylation reaction site selectivity and the like, and is suitable for being developed into a large-scale production process.

The invention discloses a preparation method and application of a high-purity cannabidiol heptyl derivative CBDP, and belongs to the technical field of organic synthesis compounds. In order to solve the technical problems of low purity, complex process and high cost of cannabidiol heptyl derivatives in the prior art, the invention provides a preparation method with high purity and simple preparation process. The key points of the technical scheme are as follows: (1) 5-heptylresorcinol and (1S, 4R)-1-methyl-4-(1-methylvinyl)-2-cyclohexene-1-alcohol are dissolved in a solvent and react under the action of a Lewis acid catalyst, and a cannabidiol heptyl derivative CBDP is obtained; (2) dissolving a cannabidiol heptyl derivative CBDP in a solvent, reacting with a derivatization reagent, and purifying to obtain an intermediate 7; and (3) dissolving the intermediate 7 in a solvent, and purifying through an enzyme hydrolysis reaction to obtain the high-purity cannabidiol heptyl derivative CBDP.

A transdermal delivery composition for the delivery to skin and the penetration of the skin includes: (a) a therapeutic effective amount of a cannabinoid mixture, wherein the cannabinoid mixture comprises cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) at a weight ratio of about 1:20 to about 20:1; (b) a hydrophilic polymer / hydrophobic polymer adduct in an amount sufficient to hold the cannabinoid composition and provide a sustain release of the cannabinoid mixture after application to skin tissue over a time period of at least 6 hours; (c) a penetrant component in an amount sufficient to assist with a transdermal penetration of the cannabinoid mixture through skin tissue once the composition has been applied to skin tissue; (d) a surfactant component in an amount sufficient to stabilize the polymer adduct and release the cannabinoid mixture from the transdermal delivery composition upon application to skin tissue; and (e) at least about 70 wt. % water. A method of application of a transdermal delivery composition to skin tissue includes applying the transdermal delivery composition to skin tissue and spreading the composition to form a film on the skin tissue. A method for formulating a transdermal delivery composition based on a desired penetration weight ratio of CBD to THC through skin tissue includes selecting a formulation weight ratio of CBD to THC for formulating the composition, wherein the weight ratio is determined by multiplying the desired penetration weight ratio of CBD to THC by a CBD / THC delivery factor, wherein the CBD / THC delivery factor.

The invention provides a wound dressing for wound hemorrhage. The wound dressing is prepared from the following components in parts by mass: 20 to 25 parts of cationic cassava starch, 10 to 13 parts of polyethylene glycol, 1.2 to 1.8 parts of xanthan gum, 0.1 to 0.2 part of cannabidiol, 6 to 8 parts of tannic acid modified chitosan, 1.8 to 2.5 parts of a polydopamine solution with the concentration of 5mg / mL and 1 to 1.5 parts of nano-hydroxyapatite. The wound dressing has an instant hemostatic effect and a long-acting tissue regeneration induction capability.

The invention relates to a method for specifically detecting tetrahydrocannabinol and hydride thereof by utilizing bridged beta-cyclodextrin, and belongs to the technical field of analysis and detection of supramolecular materials. The method comprises the following steps: firstly, combining 1, 6-hexamethylenediamine bridged bis-beta-cyclodextrin with an indicator to form a supramolecular probe; in a buffer system with a pH value of 9-11, tetrahydrocannabinol or a hydride thereof specifically competes to be combined with a cavity and displaces an indicator by utilizing a synergistic inclusion effect of a bridging subject and dissociation difference of guest molecules, so that the system is subjected to fluorescence quenching or color change, and a structural analogue cannabidiol does not generate obvious interference. The method solves the problems that the sensitivity is low and cannabidiol cannot be effectively distinguished in the prior art through cooperation of specific main body construction and environment regulation, has the advantages of being rapid in detection, high in specificity, high in accuracy and the like, and is suitable for environment monitoring and field screening.

Cannabidiol, or a pharmaceutically acceptable prodrug, derivative, salt, or solvate thereof, for use in treating or preventing recurrent pericarditis is disclosed. The effectiveness of cannabidiol in attenuating the levels of interleukin-1β (IL-1β) and IL-6, and the transcription of pro-IL-1β and NLRP3 mRNA in in vitro models are disclosed. Also disclosed are experiments showing cannabidiol to be effective in preventing an increase in the pericardial space (which is an indicator of pericardial effusion) and the pericardial thickness in an in vivo mouse model of pericarditis.

The present disclosure provides a new ring annulated cannabidiol compounds where either one or both the alpha position to OH in aromatic ring is attached to the hetero-ring through spacer, their method of preparation and use as neuroprotective and anti-inflammatory agent. The present disclosure further provides a process for preparation of the compounds.

Compositions and methods are disclosed for treating one or more symptoms of perimenopause. A composition includes a cannabidiol, a Curcuma longa extract, and / or a Lepidium meyenii extract. A method of manufacturing a composition comprises including a cannabidiol, a Curcuma longa extract, and / or a Lepidium meyenii extract in the composition. A method of administering a composition includes administering a cannabidiol, a Curcuma longa extract, and / or a Lepidium meyenii extract of the composition.

Methods and compositions relating to the treatment of degenerative disc disease are provided.SOLUTION: In some embodiments, cannabidiol is utilized to enhance the therapeutic and / or regenerative activity of fibroblasts. In other embodiments, cannabidiol is utilized to augment the reparative effects of other regenerative cells, including monocytes, mesenchymal stem cells, and / or hematopoietic stem cells. In some embodiments, cannabidiol is utilized in the culture media of regenerative cells prior to administration of said cells.SELECTED DRAWING: Figure 1

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of PTE.

Transdermal delivery devices (TDDs) that provide an easy-to-use method of delivering a consistent, steady dose of cannabidiol (CBD) are shown and described herein. The TDDs include a backing layer coated with a mixture of CBD, a polyisobutene adhesive, and plasticizer. Methods of making and using the same are also described.

The invention provides a hydrogel dressing for wound hemostasis. The hydrogel dressing is prepared from the following components in parts by mass: 8 to 20 parts of corn starch, 5 to 8 parts of polyvinyl alcohol, 0.5 to 2 parts of xanthan gum, 0.05 to 0.1 part of cannabidiol, 10 to 15 parts of glycerol, 0.5 to 1 part of panthenol, 0.3 to 0.6 part of phenoxyethanol and 0.5 to 1 part of Tween 80. In the hydrogel dressing, all the components cooperate with one another, so that the hydrogel dressing can be suitable for domestic standing medicine chests to treat daily wounds such as slight cut wounds and abrasion wounds, and is convenient for non-professionals to use.

The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.

The present technology refers to a method for treating one or more symptoms of Completely Methylated Fragile X Syndrome (Fmet) in a subject that includes administering an effective amount of cannabidiol to the subject so as to treat one or more symptoms of Fragile X Syndrome.

The invention provides anti-inflammatory and healing-promoting hemostatic powder and a preparation method thereof. The rapid hemostatic powder is prepared from the following components in percentage by mass: 10 to 15 percent of cannabidiol, 4 to 8 percent of polyvinyl alcohol, 18 to 24 percent of polyacrylamide and the balance of quaternary ammonium salt-based chitosan. All the components are synergistically matched in proper mass percent, so that the effects of good blood compatibility and cell compatibility, fast gelling, high tissue adhesion and rapid hemostasis can be achieved. Meanwhile, the hemostatic powder has the advantages of good inflammation resistance and healing promotion. The hemostatic powder is suitable for accidents, operations and other scenes. In addition, the preparation method of the hemostatic material is simple and easy to implement, does not need to depend on complex processes and equipment, and is convenient for large-scale popularization.

The invention belongs to the technical field of medicines, and discloses application of asarinol and derivatives thereof in treatment of the Dravet syndrome. The structural general formula of asarinol and the derivatives thereof is shown in (I). Researches find that in an scn1lab / zebra fish model, alpha-asarone, beta-asarone and derivatives thereof can reduce epilepsy-like discharge by 23%-93%, and the effect is obviously superior to that of stiripentanol and cannabidiol. Related pharmaceutical preparations can be prepared into capsules, dry suspensions or gels and the like, the dry suspensions are more suitable for children to take, and the capsules and the gels are suitable for adults to take. In addition, toxicological studies show that the compound is high in safety and free of remarkable developmental toxicity. The invention provides a safe and efficient novel treatment scheme for the Dravot syndrome and intractable epilepsy, and has important clinical transformation value. (I)

The utility model relates to industrial hemp extraction technical field, concretely relates to a hemp residue recovery and storage device based on industrial hemp extraction cannabigerol, including box, the inside assembly of box has the collecting device that carries out collection to impurity, the front of box is hinged with the box door, the collecting device includes roof, the roof fixed connection in the top of box, the fixed connection of electric telescopic link has in the roof inner wall bottom, the fixed connection of electric telescopic link output end bottom has the pressure plate, the fixed connection of box inner wall front has the supporting plate, the bottom of supporting plate inner wall is provided with the through -hole, the fixed connection of pressure plate top has the magnetism guide, the magnetism guide magnetic force is connected with permanent magnet. The utility model pressure plate presses down, magnetism guide and permanent magnet synchronous drop, rack drive first round tooth and second round tooth gear, first knock block and second knock block knock the sidewall of box and supporting plate bottom in proper order, through vibration stripping, solve the suspended and attached dust that traditional compression can not remove.

This invention provides a method for addressing one or more behavioral symptoms of autism spectrum disorder (ASD) in a given subject. [Solution] A method of treatment is provided in which an effective amount of cannabidiol (CBD) is administered transdermally to the target.

The present invention relates to a composition for preventing or treating periodontitis containing cannabidiol and taurine. The composition according to the present invention can effectively prevent or treat periodontitis by suppressing inflammatory factors and directly suppressing the loss of alveolar bone. In addition, it is safe for the human body and has almost no side effects, so it can be used in various ways as a material for medicines, quasi-drugs, or health functional foods.

The invention belongs to the field of pharmacy, and particularly relates to cannabidiol albumin nanoparticle polypeptide hydrogel and application thereof. The CBD albumin nanoparticles are constructed, so that the problems of low water solubility, poor in-vivo stability and the like of cannabidiol are solved; the polypeptide hydrogel long-acting sustained-release system developed by the invention enhances the drug effect of active ingredients in a periodontitis in-situ injection preparation, and has a good application prospect.

The application belongs to the technical field of biological medicine, and more particularly relates to nanoparticles TK-PSBs / CBD@Met, a preparation method therefor and application thereof. The nanoparticles TK-PSBs / CBD@Met are nanoparticles formed by wrapping cannabidiol and metformin with thione-modified lung surfactant biomimetic liposomes. In vitro experiments have confirmed that the nanoparticles TK-PSBs / CBD@Met can effectively inhibit the fibrosis process of BEAS-2B cells induced by silicon dioxide. Animal experiments have shown that the nanoparticles TK-PSBs / CBD@Met can significantly improve the damage to the lung tissue structure and abnormal deposition of collagen caused by SiO2 exposure, and alleviate the pathological progression of silicosis fibrosis.

The invention provides a wound dressing beneficial to stopping bleeding, relieving pain and promoting healing and a preparation method thereof. The wound dressing beneficial to stopping bleeding, relieving pain and promoting healing is prepared from the following components in percentage by mass: 4 to 6 percent of oxidized guar gum, 3 to 5 percent of quaternary ammonium salt chitosan, 0.1 to 0.2 percent of cannabidiol, 0.2 to 0.4 percent of 2-roots alcohol, 5 to 8 percent of polyethylene glycol and the balance of phosphate buffer. The dressing can achieve excellent effects of stopping bleeding, relieving pain and promoting healing through synergistic cooperation of all the components.

The invention discloses an anti-tumor pharmaceutical composition and application thereof, the pharmaceutical composition comprises cannabidiol and paroxetine hydrochloride, and the mass ratio of the cannabidiol to the paroxetine hydrochloride is (5: 1)-(20: 1). Research finds that cannabidiol and paroxetine hydrochloride can respectively reduce expression of PD-L1 on a tumor cell membrane through different mechanism ways, specifically, CBD promotes degradation of PD-L1 through a lysosome way; the PAR is used for promoting the degradation of the PD-L1 through a ubiquitin-proteasome way. Based on the discovery, the CBD and the PAR are further combined for use, and the result shows that compared with independent use of the CBD and the PAR, the combined use of the CBD and the PAR can play a synergistic anti-tumor role, and the CBD and the PAR have no obvious toxic and side effects and are relatively high in use safety.

The invention provides a hydrogel wound dressing capable of rapidly stopping bleeding. The hydrogel wound dressing is prepared from the following components in percentage by mass: 10 to 15 percent of polyethylene glycol, 5 to 10 percent of oxidized konjac glucomannan, 0.1 to 0.3 percent of cannabidiol, 0.5 to 2 percent of polydopamine nanoparticles, 8 to 12 percent of tannic acid modified carboxymethyl chitosan and the balance of corn starch. According to the hydrogel wound dressing, through cooperation of all the components, rapid hemostasis can be achieved, and the hydrogel wound dressing is especially suitable for domestic standing scenes, convenient to use and capable of rapidly stopping bleeding, reducing wound infection and easing pain.